Hybrid nanoparticles for combination therapy of cancer

详细信息    查看全文

• 作者：Chunbai He ; Jianqin Lu ; Wenbin Lin ; ^{wenbinlin@uchicago.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Hybrid nanoparticle ; Co-delivery ; Synergistic effect ; Combination therapy of cancer
• 刊名：Journal of Controlled Release
• 出版年：2015
• 出版时间：10 December 2015
• 年：2015
• 卷：219
• 期：Complete
• 页码：224-236
• 全文大小：3365 K

文摘

Nanoparticle anticancer drug delivery enhances therapeutic efficacies and reduces side effects by improving pharmacokinetics and biodistributions of the drug payloads in animal models. Despite promising preclinical efficacy results, monotherapy nanomedicines have failed to produce enhanced response rates over conventional chemotherapy in human clinical trials. The discrepancy between preclinical data and clinical outcomes is believed to result from the less pronounced enhanced permeability and retention (EPR) effect in and the heterogeneity of human tumors as well as the intrinsic/acquired drug resistance to monotherapy over the treatment course. To address these issues, recent efforts have been devoted to developing nanocarriers that can efficiently deliver multiple therapeutics with controlled release properties and increased tumor deposition. In ideal scenarios, the drug or therapeutic modality combinations have different mechanisms of action to afford synergistic effects. In this review, we summarize recent progress in designing hybrid nanoparticles for the co-delivery of combination therapies, including multiple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiotherapy. The in vitro and in vivo anticancer effects are also discussed.